miRNA-205: A Future Therapeutic Molecule for Liver Diseases

Cabrera, Marco; Kolli, Meghana; Jaggi, Meena; Chauhan, Subhash C.; Yallapu, Murali M.

doi:10.4155/fdd-2022-0012

Cited by 1 publication

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MiR-205, downregulated in most liver diseases, could be a diagnostic and treatment molecule. MiR-29a, miR-146a, and miR-155 also modulate HCV replication and host immune response [22]. The microRNA-29a (miR-29a) is a member of miR-29 family, whose serum levels are increased upon HCV mediated liver injury [23].…”

Section: Introductionmentioning

confidence: 99%

Circulating miRNA-192 and miR-29a as Disease Progression Biomarkers in Hepatitis C Patients with a Prevalence of HCV Genotype 3

Ullah

Rehman

Ommer

et al. 2023

Genes

View full text Add to dashboard Cite

MicroRNAs miR-29a and miR-192 are involved in inflammatory and fibrotic processes of chronic liver disease, and circulating miR-29a is suggested to diagnose fibrosis progression due to hepatitis C virus (HCV) infection. This study aimed to evaluate the expression profile of circulating miR-192 and 29a in a patient cohort with a high frequency of HCV genotype-3. A total of 222 HCV blood samples were collected and serum were separated. Patients were classified into mild, moderate, and severe liver injury based on their Child–Turcotte–Pugh CTP score. RNA was isolated from the serum and used for quantitative real-time PCR. The HCV genotype-3 (62%) was the predominant HCV genotype. In HCV patients, the serum miR-192 and miR-29a levels were significantly upregulated in comparison to healthy controls (p = 0.0017 and p = 0.0001, respectively). The progression rate of miR-192 and 29a in the patient group with mild was highly upregulated compared to patients with moderate and severe hepatitis infection. The ROC curve of miR-192 and miR-29a of moderate liver disease had a significant diagnostic performance compared to the other HCV-infected groups. The increase in miR-29a and miR-192 serum levels was even slightly higher in patients with HCV genotype-3 than in non-genotype-3 patients. In conclusion, serum miR-192 and miR-29a levels significantly increased during the progression of chronic HCV infection. The marked upregulation in patients with HCV genotype-3 suggests them as potential biomarkers for hepatic disease, independently of the HCV genotype.

show abstract

Section: Introductionmentioning

confidence: 99%